ABSTRACT
Aim To investigate the pharmacological mechanism of Weimaining in the treatment of lung ade¬nocarcinoma ( LUAD) , using a network pharmacology and molecular docking approach. Methods The active components and potential targets of Weimanin ( Rhizo- ma Fagopyri Cymosi) were screened out through TCM- SP, TCMID, BATMAN-TCM and ETCM data plat-form, and supplemented with literature. The gene ex¬pression data of LUAD were obtained from the Gen Ex¬pression Omnibus database(GEO) , and the differenti¬ally expressed genes were determined using R software. A protein-protein interaction( PPI) network of intersec¬tion targets was constructed by STRING and visualized by Cytoscape software, and GO functional annotation and KEGG pathway enrichment analysis were per¬formed by Metascape platform. Finally, molecular doc¬king studies were carried out to verify the binding of core components and targets. Results Selecting the OB and DL as filter condition, 16 active ingredients and 353 potential targets were involved. MMP-9, MMP-1, CAT and other targets were closely related to LUAD. The KEGG analysis showed that target genes were enriched in several key cancer-related signaling pathways, including the Fluid shear stress and athero¬sclerosis, Pathways in cancer, AGE-RAGE signaling pathway, p53 signaling pathway, etc. Conclusions The present study investigates the main active compo¬nents, targets and related pathways of Weimaining in the treatment of LUAD, which provides the theoretical basis and ideas for further research.
ABSTRACT
Objective To prepare cysteamine group substitutes of catechin compounds from Weimaining. Methods After thiolased by cysteamine, Weimaining was subjected to the open column chromatography on C18, and subsequently to the semipreparative high performance liquid chromatograph (HPLC) to prepare the cysteamine group substitutes of catechin compounds. Results Compounds 4β-(2-aminoethylthio)catechin, 4β-(2-aminoethylthio)epicatechin, and 4β-(2-aminoethylthio) epicatechin-3- J-gallate were obtained, and their purities were above 95%. Conclusion The method is simple and easy, and provides a reference for the preparation of the cysteamine group substitutes of catechin compounds.
ABSTRACT
Objective To prepare cysteamine group substitutes of catechin compounds from Weimaining. Methods After thiolased by cysteamine, Weimaining was subjected to the open column chromatography on C18, and subsequently to the semi-preparative high performance liquid chromatograph (HPLC) to prepare the cysteamine group substitutes of catechin compounds. Results Compounds 4β-(2-aminoethylthio)catechin, 4β-(2-aminoethylthio)epicatechin, and 4β-(2-aminoethylthio) epicatechin-3-O-gallate were obtained, and their purities were above 95%. Conclusion The method is simple and easy, and provides a reference for the preparation of the cysteamine group substitutes of catechin compounds.
ABSTRACT
Objective To evaluate the efficacy and safety of the combination of Weimaining capsule and XELOX regimen (oxaliplatin plus capecitabine) in the treatment of advanced gastric cancer patients.Methods A total of 62 patients with advanced gastric cancer who fulfilled all predetermined criteria were randomly divided into observation group and control group.The 31 patients in observation group received a combination of Weimaining capsule and XELOX regimen,the 31 patients in control group received only XELOX regimen at the same dose intensity.Each patient received at least two cycles (1 cycle =21 days) of treatment,the efficacy was assessed after two cycles.Results The median time-to-progression (TTP) of observation and control groups were 5.5 and 4.8 months,respectively.The difference had no statistical significance (P =0.238).The disease control rates (DCR) of observation group was significantly improved compared with control group [67.7 ％ (21/31) vs 41.9 ％ (13/21),P ＜ 0.05],the difference was statistically significant,while the objective response rate (ORR) of the 2 groups had no statistical difference [(32.3 ％ (10/31) vs 25.8 ％ (8/31),P ＞ 0.05].In drug safety aspects,there was no Ⅴ grade adverse reactions (deaths caused by drug) among all the patients.Rates of grades Ⅱ-Ⅳ neutrocytopenia and nausea,vomiting in observation group were obviously lower than control group [16.13 ％ (5/31) vs 38.71％ (12/31),P ＜ 0.05;12.90 ％ (4/31) vs 35.48 ％ (11/31),P ＜ 0.05],other adverse reactions between the 2 groups had no statistical difference.Conclusions A combination of Weimaining capsule and XELOX regimen in the treatment of advanced gastric cancer patients can improve DCR significantly and reduce part of adverse reaction induced by chemotherapy with satisfactory safety.This method is worthy of application widely.
ABSTRACT
AIM: To investigate the anti - tumor effect of Weimaining (WMN) on a murine Lewis lung carcinoma (3LL) and the influence on the cell cycle. METHODS: The inhibitory rate of WMN in 3LL growth was detected by replicating the model of 3LL. The effect of the drug on 3LL cell cycle and the influence of the drug on the expression of cy clin D1 protein were investigated by flow cytometry and immunohistochemical staining. RESULTS: The results showed that the inhibitory rate of drug in 3LL is 19. 14%, 33.59%, 40. 63% and 51.56% respectively at dosage ranging from 100,cells in G0 -G1 phase and decreases the expression of cyclin D1 protein. CONCLUSION: WMN inhibits the growth of 3LL cells in vivo by decreasing the expression of cyclin D1, blocking the cells in G0 - G1 phase and preventing the cells transition from G1 to S phase while DNA is replicated.
ABSTRACT
AIM: To investigate the anti-metastasis effect of weimaining, extracted from fragopyrum cymosum meissn, a Chinese medicine, on murine Lewis lung carcinoma (3LL). METHODS: The anti-metastasis effect of weimaining in vivo was detected in the grafting lung metastasis model of murine Lewis lung carcinoma. The effects of the drug on the expression of CD34 and E-cadherin were investigated by immunohistochemical staining and RT-PCR. RESULTS: Weimaining effectively inhibited the lung metastasis of 3LL at a concentration of 250 mg?kg -1?d -1, significantly suppressed the expression of CD34 and increased the expression levels of E-cadherin protein and mRNA in 3LL cells. CONCLUSIONS: Weimaining inhibits the metastasis of murine Lewis lung carcinoma (3LL) in vivo via increasing the expression of E-cadherin and decreasing microvessel density of tumor tissue.